Aarti Drugs Ltd. Share Price

Aarti Drugs: Moving up the pharma value chain

# Aarti Drugs: Moving up the pharma value chain Aarti Drugs Limited is moving beyond its traditional API business through backward integration, formulations and CDMO opportunities. The company plans ₹150–200 crore of annual capex for the next two years. The key focus is metformin. Aarti Drugs has already increased capacity to around 1,450–1,500 tonnes per month and plans to take this to 1,800–1,900 tonnes. It is also pursuing US FDA approval and plans to forward-integrate into metformin formulations. The company is also exploring CDMO opportunities in chlorosulfonation chemistry, where it already has manufacturing expertise, while expanding cardiovascular and antifungal products. This matters because APIs are more exposed to pricing cycles. Moving further downstream into regulated formulations and specialised manufacturing can potentially improve realisations and margins. Aarti Drugs has already completed around ₹600 crore of capex across Sayakha and Tarapur, while management estimates more than ₹1,200 crore of revenue potential from completed projects. **My view:** The interesting part of Aarti Drugs is the transition from an API-led business toward a more integrated pharma platform. The key test is whether the new capacity gets utilised fast enough to generate attractive returns on the capital invested. **What I'm watching:** Sayakha utilisation, metformin forward integration, regulated-market approvals, CDMO wins and return on capital. **Stance:** Capacity creation is only the first step. Execution and utilisation will determine whether the investment cycle translates into sustainable earnings growth. **Disclosure:** I am a SEBI Registered Research Analyst. Please refer to the applicable disclosures before taking any investment decision.

See More

Aarti Drugs Ltd latest updates centre on its FY26

latest updates centre on its FY26 full-year results, a management transition, and corporate actions ahead of its 41st AGM. For the year ended 31 March 2026, the company reported consolidated revenue of ₹2,568 crore, up 6.8% year on year, and consolidated PAT of ₹195 crore, up 16%, driven by new facility commercialisation and a higher share of regulated-market sales, even as raw-material cost volatility remained a concern. In Q1 FY27 (June 2026), consolidated revenue grew 19% to ₹703.6 crore and EBITDA rose 30% to ₹96.9 crore with margin expanding to 13.8%, while net profit dipped 7.1% to ₹50.1 crore due to a prior-year tax-refund base effect. The company has announced a leadership change effective October 2026, with Rashesh C. Gogri taking over as Chairman and Adhish P. Patil as Managing Director, as part of succession planning. The board also approved a Performance Stock Option Plan 2026 for up to 8 lakh options, subject to shareholder approval. Aarti Drugs will hold its 41st AGM on 26 September 2026 via video conference, with the record date for voting eligibility on 19 September and remote e-voting from 23–25 September.

See More

Technical Analysis Aarti Drugs

The stock

is showing a short-term recovery trend after forming a base near ₹325–350. It has gradually formed higher lows and is currently trading around ₹431 indicating improving buying interest. However the stock is now approaching an important resistance zone so a breakout confirmation is needed for further upside. Support & Resistance immediate support is around ₹415–405 followed by stronger support near ₹390–375. On the upside ₹435–450 is the immediate resistance zone. A sustained close above ₹450 with strong volume can strengthen the bullish setup and open the way towards ₹475–500. Short-Term Outlook: The setup is cautiously bullish while the stock remains above ₹405–415. Buyers can consider fresh entry on a decisive breakout above ₹450 or on a controlled pullback towards support. Existing holders can continue to hold with a trailing stop-loss below ₹405. A close below ₹390 would weaken the current recovery structure.

See More

Aarti Drugs: Diversified Portfolio Supports Growth Prospects

Aarti Drugs continues to strengthen its position in the pharmaceutical and specialty chemicals segment, supported by a diversified product portfolio and established manufacturing capabilities. The company operates across APIs, formulations, specialty chemicals and pharmaceutical intermediates, serving both domestic and international markets. Focus on product development, capacity expansion and operational efficiency remains important for sustaining growth. Export opportunities and increasing demand for pharmaceutical ingredients can provide additional avenues, while raw-material prices, regulatory requirements, pricing pressure and global market conditions remain key factors to monitor. Continued investment in manufacturing capabilities and a broader product mix could help the company strengthen its competitive position over the longer term. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes ***** must verify information before investing and consider their financial position & risk profile. please read full disclosure disclaimer in given link visit website www dot investmentcure dot com *****

See More

Aarti Drugs and Aarti Pharmalabs both reported strong financial updates this week.

Aarti Drugs and Aarti Pharmalabs both reported strong financial updates this week. Aarti Drugs posted a 19% YoY revenue growth in Q1 FY27 with major capacity expansion plans, while Aarti Pharmalabs announced Q4 FY26 results showing revenue growth but a sharp decline in profit margins. Additionally, Aarti Pharmalabs approved a ₹149 crore capex for new manufacturing capacity. 📊 Latest Updates on Aarti Pharma Companies 🔹 Aarti Drugs Ltd (Q1 FY27 – June 2026) Consolidated Revenue: ₹703.6 crore (+19% YoY) EBITDA: ₹96.9 crore (+30% YoY) PAT: ₹50.1 crore (adjusted growth ~29% YoY excluding tax refund) Domestic Revenue Growth: +25% Export Revenue Growth: +12% Specialty Chemicals: Sales surged 149% to ₹82 crore, driven by the new Sayakha plant. Capacity Expansion Plans: Metformin capacity to scale from 1,400 tons/month → 2,200 tons/month (new USFDA-approved block). Methyl salicylate derivatives capacity planned at 350–400 tons/month. Margins: EBITDA margin expanded to 13.8%, targeting 15% in coming quarters. 🔹 Aarti Pharmalabs Ltd (Q4 FY26 – March 2026) Total Revenue: ₹582.64 crore (+3.35% YoY) Operating Profit: ₹101.97 crore (-16.97% YoY) Net Profit (PAT): ₹61.12 crore (-30.81% YoY) Operating Margin: 17.5% (down 19.66% YoY) EPS: ₹6.74 (down from ₹7.20 YoY) Stock Movement (10 Aug 2026): BSE: ₹821.45 (+20%) NSE: ₹800 (+16.64%) Trend: Technical analysis suggests reversal of bullish momentum; short-term outlook bearish. 🔹 Aarti Pharmalabs Ltd (Q1 FY27 – June 2026) Consolidated Revenue: ₹536 crore (+38.7% YoY) Consolidated PAT: ₹76.14 crore (+65.3% YoY) Standalone PAT: ₹71.31 crore (+49.4% YoY) Capex Approval: ₹149 crore for new intermediate manufacturing block (to serve CDMO customers). Leadership Changes: Effective October 1, 2026.

See More